Addex Therapeutics (ADXN) Stock Statistics & Valuation Metrics

Addex Therapeutics has a market cap or net worth of CHF5.31M. The enterprise value is CHF5.38M.

Addex Therapeutics has 218,654,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Addex Therapeutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -54.47%.

The current PE Ratio of Addex Therapeutics is ―. Addex Therapeutics’s PEG ratio is 0.00503.

In the last 12 months, Addex Therapeutics had revenue of 173.00K and earned -6.73M in profits. Earnings per share was -0.06.

In the last 12 months, operating cash flow was -2.17M and capital expenditures 0.00, giving a free cash flow of -2.17M billion.

Addex Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Addex Therapeutics upcoming earnings date is Jun 15, 2026, TBA (Confirmed).

Addex Therapeutics as a current ratio of 1.40, with Debt / Equity ratio of 0.73%

In the past 12 months, Addex Therapeutics has paid 0.00 in taxes.

Addex Therapeutics EV to EBITDA ratio is -1.64, with an EV/FCF ratio of -2.12.

Addex Therapeutics has CHF1.64M in cash and marketable securities with CHF34.69K in debt, giving a net cash position of CHF1.60M billion.

Gross margin is -4.78%, with operating margin of -1627.17%, and net profit margin of -3889.60%.

The average price target for Addex Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―